Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib Journal Article
| Authors: | Sharma, M.; Ravandi, F.; Bayraktar, U. D.; Chiattone, A.; Bashir, Q.; Giralt, S.; Chen, J.; Qazilbash, M.; Kebriaei, P.; Konopleva, M.; Andreeff, M.; Cortes, J.; McCue, D.; Kantarjian, H.; Champlin, R. E.; de Lima, M. |
| Article Title: | Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib |
| Abstract: | Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT). Sorafenib, an inhibitor of multiple kinases including FLT3, has shown promising activity in FLT3-ITD-positive AML. We treated 16 patients with FLT3-ITD-positive AML who relapsed after HSCT with sorafenib alone (n = 8) or in combination with cytotoxic chemotherapy (n = 8). The number of circulating blasts decreased in 80% of cases, but none of the patients achieved complete remission (CR); 3 achieved partial remission. Two patients were bridged to a second transplantation but both relapsed within 3 months of the transplantation. Median overall survival (OS) was 83 days, with none surviving more than a year. Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Preventive strategies after HSCT may be more suitable for these high-risk patients. © 2011 American Society for Blood and Marrow Transplantation. |
| Keywords: | adult; cancer survival; clinical article; treatment response; aged; middle aged; retrospective studies; transplantation, homologous; young adult; acute granulocytic leukemia; gene mutation; overall survival; leukemia, myeloid, acute; fatigue; sorafenib; cancer combination chemotherapy; diarrhea; monotherapy; side effect; treatment duration; antineoplastic agents; benzenesulfonates; pyridines; combined modality therapy; cytarabine; multiple cycle treatment; antineoplastic combined chemotherapy protocols; recurrence; stem cell transplantation; hematopoietic stem cell transplantation; alanine aminotransferase blood level; protein kinase inhibitors; allogeneic hematopoietic stem cell transplantation; hyperbilirubinemia; idarubicin; flt3 ligand; leukemia relapse; azacitidine; leukemia remission; blast cell; acute myeloid leukemia; fms-like tyrosine kinase 3; flt3 |
| Journal Title: | Biology of Blood and Marrow Transplantation |
| Volume: | 17 |
| Issue: | 12 |
| ISSN: | 1083-8791 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2011-12-01 |
| Start Page: | 1874 |
| End Page: | 1877 |
| Language: | English |
| DOI: | 10.1016/j.bbmt.2011.07.011 |
| PROVIDER: | scopus |
| PUBMED: | 21767516 |
| PMCID: | PMC4061979 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 9 December 2011" - "CODEN: BBMTF" - "Source: Scopus" |
